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The effect of synthetic porcine brain natriuretic peptide (pBNP), a novel brain peptide with sequence homology to a- 
human atria1 natriuretic peptide (hANP), on receptor binding and cGMP generation, was studied in cultured rat vascular 
smooth muscle cells (VSMC) and compared with that of a-hANP. Y-pBNP bound to the cells in a time-dependent 
manner similar to that of iZ51-a-hANP. Scatchard analysis indicated a single class of binding sites for pBNP with affinity 
and capacity identical to those of a-hANP. pBNP and a-hANP were almost equipotent in inhibiting the binding of either 
radioligand and stimulating intracellular cGMP generation. These data indicate that BNP and ANP interact with the 
same receptor sites to activate guanylate cyclase in rat VSMC. 
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1. INTRODUCTION 
Atria1 natriuretic peptide (ANP) is a potent 
diuretic and vasodilatory peptide hormone 
originally isolated from the mammalian heart [ 1,2] 
and subsequently from the brain [3]. A novel 
natriuretic peptide has recently been identified in 
the porcine (p) brain, designated as brain 
natriuretic peptide (BNP) [4]. pBNP comprises 26 
amino acid residues with a remarkable homology 
to, but definitely distinct from, the known se- 
quence of ANPs. pBNP induces diuretic- 
natriuretic and hypotensive effects in rats and 
chick rectum relaxant activity in a manner similar 
to those of a-human (h) ANP. Therefore, it is sug- 
gested that BNP may function in concert with 
ANP to regulate the homeostatic balance of body 
fluid and blood pressure through a dual 
mechanism [4]. 
Correspondence address: Y. Hirata, Hypertension-Endocrine VSMCs isolated from aorta of adult Wistar rats were sub- 
Division, National Cardiovascular Center Research Institute, cultured (lO-15th passages) and used in binding experiments as 
Suita, Osaka 565, Japan reported [5]. Briefly, confluent (2 x 10s) cells were usually in- 
However, whether BNP acts on the target cells 
via the mechanism identical to or distinct from that 
of ANP remains obscure. To address this intrigu- 
ing issue, we have studied the effect of synthetic 
pBNP on receptor binding and cGMP generation 
in cultured rat vascular smooth muscle cells 
(VSMC) which have abundant ANP receptors 
functionally coupled to the guanylate cyclase 
system [5] and compared its effect 
cr-hANP . 
2. MATERIALS AND METHODS 
2.1. Materials 
with that of 
pBNP synthesized by means of a solution method possesses 
diuretic-natriuretic and hypotensive effects comparable to those 
of natural pBNP [4]. Synthetic cu-hANP was obtained from the 
Peptide Institute (Osaka). Iodination of pBNP and cr-hANP 
was performed by the lactoperoxidase method [5] and resulted 
in activities of -100 and -150 rCi/pg, respectively. 
2.2. Binding experiment 
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cubated at 24°C for 60 min with ‘251-pBNP or “‘1-o-hANP in 
Hanks’ balanced salt solution (pH 7.4), containing 0.1% bovine 
serum albumin essentially according to [5]. Specific binding was 
determined by subtracting nonspecific binding in the presence 
of excess (10e6 M) unlabeled pBNP or cr-hANP from total 
binding. 
2.3. Down-regulation of ANP receptors 
ANP receptors were down-regulated by incubating VSMC 
(10’ cells) with IO-* M pBNP or cu-hANP in serum-free medium 
at 37°C for 24 h. After incubation, cells were washed extensive- 
ly with ice-cold medium to remove unbound ligand and rein- 
cubated in fresh medium at 37°C for 2 h to permit degradation 
of the bound ligand as described [6]. Cells were then subjected 
to saturable binding studies using “‘I-cr-hANP. 
2.4. Determination of intracellular cGMP 
VSMCs were incubated with or without pBNP or cr-hANP at 
37°C for 10 min in the presence of 0.5 mM methylisobutylxan- 
thine and the content of intracellular cGMP determined by 
radioimmunoassay (RIA) as in [5,6]. 
BOUND (@I 
I 2.5 
‘25 I- hANP (nM) 
I 
BOUND (WI 
fl 5 x 10-n lo-‘0 5 x W’s 10-s 5 x 10-9 18 
0 0.1 0.25 0.5 1 
Izal- p%NP (nM) 
2.5 
hANP or pBNP (M) 
Fig.1. Saturable binding of 1251~-hANP and iz51-pBNP to 
cultured rat VSMC. Confluent (2 x 10’) cells were incubated 
with various doses of ‘251-cy-hANP (A) and ‘Z51-pBNP (B) at 
24°C for 60 min. Specific binding of 1Z51-ohANP and lz51- 
pBNP was 85-90 and 90-94% of total binding, respectively. 
Each point is the mean of three experiments; bar shows SE 
Fig.2. Competitive binding of ‘251~-hANP and r2’I-pBNP to 
cultured rat VSMC. Confluent (2 x 16) cells were incubated at 
24°C for 60 min with 1 nM ‘251a-hANP (A) and ‘251-pBNP (B) 
in the absence and presence of various doses of c&ANP (0) 
and pBNP (0). Results are expressed as the percentage of 
specific binding in the absence of peptides (Bo); each point is the 
mean of duplicate dishes. Specific binding of tZ51-cu-hANP and 
(inset) Scatchard plot of binding data. iz51-pBNP was 81 and 82070, respectively. 
3. RESULTS 
The time courses for binding of lz51-pBNP and 
‘251-(U-hANP to rat VSMC at 24°C were essentially 
similar, attaining apparent equilibrium after 
60 min; nonspecific binding of r2’I-pBNP and r2’I- 
cu-hANP was lo-15% of total binding (not 
shown). Equilibrium binding of lz51-pBNP and 
‘251-a-hANP was a saturable process (fig. 1). Scat- 
chard plots (fig. 1, inset) revealed the presence of a 
single class of binding sites for both pBNP and LY- 
hANP: their apparent dissociation constants (Kd 
2.5 x 10-r’ M) and maximal binding capacities 
(B,, 70000 sites/cell) were equal. Competitive 
binding of 1251-cr-hANP (fig.2A) and lZ51-pBNP 
(fig.2B) by unlabeled u-hANP and pBNP was 
studied; whereas hANP was about 2-fold more po- 
tent than pBNP in displacing the binding of ‘251- 
hANP or pBNP (M) 
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Fig.3. Effects of cu-hANP and pBNP on formation of 
intracellular cGMP in cultured rat VSMCs. Confluent (2 x 10s) 
cells were incubated at 37°C for 10 min in the absence (0) and 
presence of various doses of cr-hANP (0) and pBNP (0). 
Concentrations of intracellular cGMP were determined by RIA. 
Each point is the mean of triplicate dishes: bar shows SE. 
0. 
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Fig.4. Scatchard plots of saturable binding of ‘251-uhANP to 
cultured rat VSMC after ANP receptor down-regulation. 
VSMCs (10s cells) were preincubated at 37°C for 24 h in the 
absence (0) and presence of lo-* M unlabeled a-hANP (0) or 
pBNP (A), after which the cells were subjected to binding 
experiments as described in section 2. Each point is the mean of 
two experiments. 
cw-hANP from its receptor sites, hANP and pBNP 
equally inhibited the binding of “‘1-pBNP. 
As shown in fig.3, pBNP and cr-hANP similarly 
stimulated cGMP formation with an approximate 
EDso of 5 x lo-’ M. No additive effect was in- 
duced on simultaneous addition of pBNP and cy- 
hANP at maximal doses (not shown). 
Pretreatment with either pBNP or cu-hANP at an 
equimolar concentration (lo-* M) induced a mark- 
ed and similar reduction in B,, (40000 sites/cell) 
without changing its affinity (& 2 x lo-” M) 
compared to B,, (80000 sites/cell) in untreated 
cells (fig.4). 
4. DISCUSSION 
BNP, a novel natriuretic peptide comprising 26 
amino acid residues isolated from porcine brain, 
shows a remarkable homology to, but is distinct 
from, cY-hANP, and possesses biological activity 
comparable to that of cY-hANP as determined from 
the in vivo diuretic-natriuretic and hypotensive ef- 
fects in rats [4]. 
Using radioligand-binding experiments, the pre- 
sent study clearly demonstrates that synthetic 
pBNP binds to ANP receptors in cultured rat 
VSMC essentially in the manner as a-hANP; Scat- 
chard analysis of binding data shows that the 
binding capacity and affinity of BNP appear to be 
identical to those of ANP, suggesting that BNP 
and ANP interact with the same binding sites. Our 
results that unlabeled pBNP and cu-hANP are 
almost equipotent in competing with either 
radioligand to its binding sites are also compatible 
with this notion. 
We have previously shown that cultured rat 
VSMCs have ANP receptors functionally coupled 
to guanylate cyclase [5,6]. The present study also 
shows that pBNP is equipotent to hANP in 
stimulating cGMP formation in rat VSMC. The 
ring structure formed by the intramolecular 
disulfide linkage in the ANP molecule that is essen- 
tial for its biological activity [7] as well as for 
stimulating guanylate cyclase [6] is highly con- 
served in the BNP molecule, although four out of 
17 amino acid residues in this region are replaced 
[4]. Therefore, it seems most likely that BNP- 
induced cGMP formation is mediated through the 
same receptors as for ANPl 
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Previously, we have demonstrated that vascular 
ANP receptors are under the control of a 
homologous down-regulation mechanism [6]. The 
present result that long-term exposure of pBNP 
leads to a substantial reduction in total vascular 
ANP receptor number without changing its affini- 
ty in a similar fashion to that of a-hANP also lends 
further support to the contention that BNP and 
ANP interact with the same receptor sites to induce 
homologous receptor down-regulation. 
The questions as to whether BNP acts on the 
unique receptor distinct from ANP receptors in 
other target tissues including the central nervous 
system, and whether BNP circulates in the blood to 
act in harmony with ANP remain to be clarified. 
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